At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Rimegepant in Moderate Plaque-type Psoriasis
In Brief
A Phase 2 clinical trial evaluating Rimegepant and Placebo for Psoriasis. Completed, enrolled 41 participants across 2 sites.
Detailed Summary
The purpose of this study is to examine the use of a new investigational medication for the treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally administered small molecule competitive inhibitor of the calcitonin gene-related peptide (CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade name Nurtec for the treatment of acute migraine. However, rimegepant has not been studied in the treatment of moderate plaque-type psoriasis and is investigational for this indication.
Study Details
Timeline
Interventions
Active Agent
Placebo Comparator